Comparative safety of PD-1 and PD-L1 inhibitors in advanced solid tumors: a real-world cohort study with competing risk analysis

Key Points

• The study aims to compare the safety of PD-1 and PD-L1 inhibitors in advanced solid tumors while considering competing mortality risks.
• Conducted a real-world cohort analysis of patients with advanced solid tumors.
• Evaluated the incidence of immune-related adverse events (irAEs) associated with both inhibitor types.
• Applied competing risk analysis to assess mortality impact on safety outcomes.
• PD-L1 inhibitors showed a lower incidence of certain irAEs compared to PD-1 inhibitors.
• Competing mortality notably influenced the safety profiles of both therapies.
• Findings underscore the importance of accounting for mortality in safety assessments.